JP2008500375A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500375A5
JP2008500375A5 JP2007515532A JP2007515532A JP2008500375A5 JP 2008500375 A5 JP2008500375 A5 JP 2008500375A5 JP 2007515532 A JP2007515532 A JP 2007515532A JP 2007515532 A JP2007515532 A JP 2007515532A JP 2008500375 A5 JP2008500375 A5 JP 2008500375A5
Authority
JP
Japan
Prior art keywords
natriuretic compound
natriuretic
modifying moiety
formula
compound complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007515532A
Other languages
English (en)
Other versions
JP2008500375A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/019249 external-priority patent/WO2005116655A2/en
Publication of JP2008500375A publication Critical patent/JP2008500375A/ja
Publication of JP2008500375A5 publication Critical patent/JP2008500375A5/ja
Pending legal-status Critical Current

Links

Claims (19)

  1. ナトリウム利尿分子NPR−A結合部位と、少なくとも1つの修飾部分複合部位と、を含む生物活性ナトリウム利尿化合物と、
    前記修飾部分複合部位に付着した少なくとも1つの修飾部分と、
    を含むナトリウム利尿化合物複合体であって、
    前記ナトリウム利尿化合物複合体が、対応する非複合ナトリウム利尿化合物に対して酵素分解に対する耐性の増大、循環半減期の増大、バイオアベイラビリティの増大、および効果の持続期間の延長から成る群から選択される1つもしくはそれ以上の利点を示す、ナトリウム利尿化合物複合体。
  2. 前記ナトリウム利尿化合物が、ペプチド、もしくは脳ナトリウム利尿ペプチドの生物活性ペプチド断片、心房性ナトリウム利尿ペプチド、C型ナトリウム利尿ペプチド、またはデンドロアスピス(dendroaspis)ナトリウム利尿ペプチドを含む、請求項1に記載のナトリウム利尿化合物複合体。
  3. 前記ナトリウム利尿化合物が、Lys3Arg、Lysl4Arg、Arg30Lys、Lys27Arg、およびArg31Lysから成る群から選択される1つもしくはそれ以上の変異体を有する天然hBNP配列を含む、請求項1に記載のナトリウム利尿化合物複合体。
  4. 前記ナトリウム利尿化合物が、1つもしくはそれ以上の挿入、欠失、または伸長を有する天然hBNP配列を含む、請求項1に記載のナトリウム利尿化合物複合体。
  5. 前記修飾部分が、
    Figure 2008500375

    [式中、各々のCは、独立して選択され、m個の炭素を有するアルキル部分であり、かつ、mは1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、または20であるとともに、
    各々のPAGは、独立して選択され、n個のサブユニットを有するポリアルキレングリコール部分であり、かつ、nは1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、または25であり、
    各々Xは、独立して選択され、架橋部分である。]を有する、請求項1に記載のナトリウム利尿化合物複合体。
  6. 前記修飾部分が、式
    Figure 2008500375

    (式1A)
    を有する、請求項5に記載のナトリウム利尿化合物複合体。
  7. 前記修飾部分が、式
    Figure 2008500375

    (式1B)
    を有する、請求項5に記載のナトリウム利尿化合物複合体。
  8. 過剰なレベルの細胞外液の治療のための薬剤の製造における、請求項1ないし7のいずれに記載のナトリウム利尿化合物複合体の使用。
  9. 前記修飾部分が、式
    Figure 2008500375
    を有する、請求項1に記載のナトリウム利尿化合物複合体。
  10. 前記修飾部分が、式
    Figure 2008500375
    を有する、請求項5に記載のナトリウム利尿化合物複合体。
  11. 前記修飾部分が、式
    Figure 2008500375
    を有する、請求項1に記載のナトリウム利尿化合物複合体。
  12. 前記修飾部分が、式
    Figure 2008500375
    を有する、請求項5に記載のナトリウム利尿化合物複合体。
  13. 前記修飾部分が、式
    Figure 2008500375
    を有し、
    かつ、前記ナトリウム利尿化合物がhBNPであり、前記修飾部分がLys3で結合されるとともに、前記ナトリウム利尿化合物複合体がモノ複合体である、請求項5に記載のナトリウム利尿化合物複合体。
  14. 前記ナトリウム利尿化合物が、hBNPである、請求項5ないし13のいずれかに記載のナトリウム利尿化合物複合体。
  15. 前記ナトリウム利尿化合物が、hBNPであり、前記修飾部分がLys3で結合されており、かつ前記ナトリウム利尿化合物複合体が、モノ複合体である、請求項5ないし13のいずれかに記載のナトリウム利尿化合物複合体。
  16. 上記請求項のいずれかに記載のナトリウム利尿化合物複合体および薬学的に許容される担体を含む、医薬組成物。
  17. 請求項5ないし13に記載のナトリウム利尿化合物複合体を製造する方法であって、前記方法が前記修飾部分を前記ナトリウム利尿化合物に化学的に結合する工程を含む、方法。
  18. 上記請求項のいずれかに記載のナトリウム利尿化合物複合体の薬学的に純粋な組成物。
  19. mが1であり、Xが−O−であり、nが4であり、Cが−CHである、請求項5に記載のナトリウム利尿化合物複合体。
JP2007515532A 2004-05-26 2005-05-26 ナトリウム利尿化合物、複合体、およびその使用 Pending JP2008500375A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57443604P 2004-05-26 2004-05-26
PCT/US2005/019249 WO2005116655A2 (en) 2004-05-26 2005-05-26 Natriuretic compounds, conjugates, and uses thereof

Publications (2)

Publication Number Publication Date
JP2008500375A JP2008500375A (ja) 2008-01-10
JP2008500375A5 true JP2008500375A5 (ja) 2008-05-22

Family

ID=35451511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515532A Pending JP2008500375A (ja) 2004-05-26 2005-05-26 ナトリウム利尿化合物、複合体、およびその使用

Country Status (14)

Country Link
US (3) US7648962B2 (ja)
EP (1) EP1776132A4 (ja)
JP (1) JP2008500375A (ja)
KR (1) KR20070050876A (ja)
CN (1) CN101027073A (ja)
AU (1) AU2005248860A1 (ja)
BR (1) BRPI0511588A (ja)
CA (1) CA2568363A1 (ja)
IL (1) IL179521A0 (ja)
MX (1) MXPA06013810A (ja)
NZ (1) NZ552210A (ja)
RU (1) RU2388765C2 (ja)
WO (1) WO2005116655A2 (ja)
ZA (1) ZA200610700B (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
EP3404102B1 (en) 2004-04-21 2021-08-11 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
WO2006005140A2 (en) 2004-07-15 2006-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
US20080207505A1 (en) * 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
KR101529318B1 (ko) * 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
US20080064045A1 (en) 2006-09-07 2008-03-13 Huaiqin Wu Biomarker fragments for the detection of human BNP
US20080181903A1 (en) * 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
KR20080098216A (ko) * 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
EP2150811B1 (en) * 2007-05-08 2013-01-16 Abbott Laboratories Human b-type natriuretic peptide assay having reduced cross-reactivity with other peptide forms
CA2693303C (en) * 2007-07-20 2017-11-07 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
EP2612868B1 (en) * 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
JP2011504506A (ja) * 2007-11-21 2011-02-10 バイオマリン ファーマシューティカル インコーポレイテッド C型ナトリウム利尿ペプチドの変異体
US20090286329A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratoires Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
US20090286256A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratories Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
US8449872B2 (en) * 2008-09-19 2013-05-28 Nektar Therapeutics Polymer conjugates of nesiritide peptides
EP2898900B1 (en) * 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
US20110171161A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of protegrin peptides
CA2758581C (en) * 2009-05-20 2022-06-14 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
CA2768810C (en) * 2009-07-23 2014-05-20 Igisu Co., Ltd. Skin external-preparation composition
JP5893561B2 (ja) * 2009-09-25 2016-03-23 シャイア・オーファン・セラピーズ・ゲーエムベーハーShire Orphan Therapies GmbH 新規npr−bアゴニスト
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
CN102260345A (zh) * 2011-05-17 2011-11-30 上海格尼生物技术有限公司 一种固相多肽合成人脑钠素的制备方法
WO2013032784A1 (en) 2011-08-30 2013-03-07 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2013070741A1 (en) * 2011-11-11 2013-05-16 Mayo Foundation For Medical Education And Research Methods and materials for regulating natriuretic polypeptide function
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014209229A1 (en) * 2013-06-25 2014-12-31 National University Of Singapore Vasodilation peptides and uses thereof
EP3083701B1 (en) * 2013-12-17 2019-08-07 Novo Nordisk A/S Enterokinase cleavable polypeptides
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
US10449236B2 (en) 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
JPWO2016194855A1 (ja) * 2015-05-29 2018-06-07 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬、外用剤および化粧料
WO2017031114A1 (en) 2015-08-17 2017-02-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
KR102518217B1 (ko) * 2016-01-08 2023-04-04 아센디스 파마 그로우쓰 디스오더스 에이/에스 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
JP2019513711A (ja) 2016-04-01 2019-05-30 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES
EP3500289A4 (en) 2016-08-18 2020-05-06 Alexion Pharmaceuticals, Inc. METHODS OF TREATING TRACHEOBRONCHOMALACIA
EP3500592A4 (en) * 2016-08-18 2020-08-12 National University of Singapore PEPTIDES WITH VASODILATOR AND / OR DIURETIC FUNCTIONS
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
RU2656188C1 (ru) * 2017-05-03 2018-06-04 Общество с ограниченной ответственностью "Анкрим" (ООО "Анкрим") Синтетическое анальгетическое средство пептидной природы и способ его применения
AU2018328208A1 (en) 2017-09-05 2020-04-23 Torque Therapeutics, Inc. Reversible linkers and use thereof
AU2018328209A1 (en) 2017-09-05 2020-04-23 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
KR102546103B1 (ko) * 2018-03-20 2023-06-21 니치유 가부시키가이샤 분기형 단분산 폴리에틸렌 글리콜, 중간체 및 그 제조 방법
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
KR102022118B1 (ko) * 2019-01-07 2019-09-18 주식회사 아스트로젠 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물
CN111848776B (zh) * 2020-08-31 2022-03-18 江苏璟泽生物医药有限公司 聚乙二醇修饰的rhBNP及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2410789C2 (de) * 1974-03-07 1980-08-07 Hoechst Ag, 6000 Frankfurt Verfahren zum Kaltmahlen von Cellulosederivaten
US4130647A (en) * 1977-07-08 1978-12-19 Pfizer Inc. Methods for treating congestive heart failure and ischemic heart disease
EP0083367A1 (en) * 1981-07-02 1983-07-13 WALTON, Alan G. Glycosaminoglycan drug complexes
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US5037741A (en) * 1986-08-18 1991-08-06 The Coca Cola Company Enzymatic method for the synthesis and separation of peptides
JP2544929B2 (ja) 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US20020086843A1 (en) * 1989-03-01 2002-07-04 Daiichi Pure Chemicals Co., Ltd. Physiologically active polypeptide and DNA
US5342940A (en) 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
US5108568A (en) 1989-07-07 1992-04-28 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
JP2665850B2 (ja) * 1991-11-14 1997-10-22 塩野義製薬株式会社 hBNPのC端を認識するモノクロ−ナル抗体
GB9211686D0 (en) * 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5512459A (en) * 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
US5569794A (en) * 1994-05-24 1996-10-29 Alliedsignal Inc. Vapor phase process for producing hydroflourocarbons from perchloroethylene having a phenolic inhibitor
US6037145A (en) * 1994-09-07 2000-03-14 Suntory Limited Process for production of protein
NO319913B1 (no) * 1994-12-09 2005-10-03 Shionogi & Co Fremgangsmate til sandwichimmunoassay for N-peptid
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
ATE297950T1 (de) 1996-03-04 2005-07-15 Scios Inc Testverfahren und reagenzien zur quantifizierung von hbnp
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
WO1998045329A1 (en) 1997-04-04 1998-10-15 Novo Nordisk A/S Natriuretic peptide derivatives
US6495514B1 (en) 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
WO1999046283A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6117644A (en) * 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
ATE220917T1 (de) 1999-01-26 2002-08-15 Lilly Co Eli Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
AU765753B2 (en) 1999-05-17 2003-09-25 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2004011498A2 (en) 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives
WO2000071576A2 (en) * 1999-05-24 2000-11-30 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (ko) 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
DE60115465T2 (de) * 2000-08-29 2006-08-03 Nobex Corp. Immunoregulierende verbindungen, deren derivate und ihre verwendung
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
ATE446971T1 (de) 2001-09-07 2009-11-15 Biocon Ltd Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
DE60331584D1 (de) 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen

Similar Documents

Publication Publication Date Title
JP2008500375A5 (ja)
RU2388765C2 (ru) Натрийуретические соединения, конъюгаты и их применение
CN1081638C (zh) 噻吩并嘧啶化合物
ATE459370T1 (de) Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
JP2004514663A5 (ja)
JP2021100937A5 (ja)
EP3518982A1 (en) Incremental dose finding in controlled-release pth compounds
US20160206746A1 (en) Method of preparing dendritic drugs
JP2005525302A5 (ja)
NZ597499A (en) Compounds and compositions for delivering active agents
JP2006526031A5 (ja)
GEP20063860B (en) Chemically-modified human growth hormone conjugates
JP2007510619A5 (ja)
JP2004533444A5 (ja)
JP2010517955A5 (ja)
CY1114241T1 (el) Ν-αρυλοσουλφονυλ-3-αμινοαλκοξυινδολια
JP2013525414A5 (ja)
EP2075250A3 (en) Thrombin receptor antagonists
US20230381284A1 (en) Controlled-Release PTH Compound
TWI770010B (zh) 聚乙二醇衍生物及其用途
JP2004517098A5 (ja)
JP2001200034A5 (ja)
JP2002520316A5 (ja)
JP2009541288A5 (ja)
RU2323211C2 (ru) Новые производные бензимидазола, способы их получения, их применение и содержащая их фармацевтическая композиция